Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
Recent: |
|
Past: |
|
A new medicine represents a dramatic advance for patients with a rare condition called pulmonary arterial hypertension — and a return to heart disease for Merck, which long had a legendary presence in cardiology. → Read More
Promoting a cardiovascular drug requires a huge marketing lift, and Esperion has a market capitalization of just $500 million. → Read More
An implantable heart clip from Abbott Laboratories led to reductions in hospitalization and death compared to standard care in a study enrolling severely ill patients, an endorsement of a device whose benefits have long been divisive. → Read More
A new generation of obesity drugs is transforming patients’ lives, dividing medical experts, and spurring the biggest business battle in years. And pharma is steering the discussion. → Read More
Results for Nexletol, a cholesterol-lowering pill, suggest it will be useful for people at high risk for heart attacks who are unable or unwilling to take statins. → Read More
Eli Lilly, one of the largest makers of insulin, said it would make dramatic cuts to the prices of several of its older insulin products in an effort to lower costs for consumers whose insulin is not fully paid for by insurance. → Read More
The sweetener erythritol, which is becoming increasingly popular in snack bars and low-sugar ice cream substitutes, may increase the risk of heart attacks and strokes, according to a new study. → Read More
Christi Shaw, the CEO of Gilead’s Kite Pharmaceuticals cell therapy unit, is leaving the company, Gilead said Friday in a statement. → Read More
With $520 million in hand, two entrepreneurs are trying to upend the biotech funding model with Curie.Bio. → Read More
Sanofi head of R&D John Reed is leaving the pharmaceutical giant to pursue a new opportunity, the company announced Monday. → Read More
Bayer named former Roche executive Bill Anderson as its new CEO, a decision that follows escalating pressure from shareholders. → Read More
A new antidepressant study may hold clues about the future direction of Verily, the high-profile Alphabet spinout. → Read More
Advisers to the FDA voted Thursday to back a plan whereby all Covid vaccines would move to the formulation used for the updated boosters, a step toward the goal of creating a single annual Covid shot for most Americans. → Read More
Scientists at the FDA propose making Covid vaccinations a regular, once-a-year shot that is updated to match current strains of the SARS-CoV-2 virus. → Read More
Verily plans to lean on its chronic disease care spinout Onduo as it looks to build a door into the lucrative world of running research. → Read More
Moderna’s vaccine against the respiratory syncytial virus, or RSV, reduced the rate of lower respiratory disease in people over 60 in a Phase 3 trial, the company said Tuesday. → Read More
Relive the return to an in-person J.P. Morgan Healthcare Conference with the STAT reporters who attended. → Read More
Ginkgo, a company that said its engineered cells could help make almost anything, is trying to drum up business. → Read More
Verily announced a major reorganization and layoffs Wednesday. The company told STAT executives Jessica Mega and Vivian Lee have left the Alphabet spinout. → Read More
Illumina said its consolidated earnings per share would be in the range of $1.25, dramatically below the expected $2.99 per share. → Read More